Dr. Claus Roehrborn, MD
What this data tells you about Dr. Roehrborn
Dr. Claus Roehrborn is an urology physician in Dallas, TX, with 20 years in practice. Based on federal Medicare data, Dr. Roehrborn performed 5,151 Medicare services across 2,566 unique beneficiaries.
Between the years covered by Open Payments, Dr. Roehrborn received a total of $254,274 from 26 pharmaceutical and/or device companies across 156 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in urology physician. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Roehrborn is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| BCG treatment for bladder cancer | 1,685 | $2 | $10 |
| Office visit, established patient (30-39 min) | 875 | $88 | $344 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 533 | $134 | $2,030 |
| Office visit, established patient (20-29 min) | 375 | $57 | $232 |
| Bladder ultrasound after voiding | 331 | $8 | $80 |
| Electronic assessment of bladder emptying | 309 | $10 | $340 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 140 | $3 | $395 |
| New patient office visit (45-59 min) | 122 | $113 | $533 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 95 | $25 | $143 |
| Ultrasound scan of pelvic region through rectum | 74 | $104 | $458 |
| Instillation of anti-cancer drug into bladder | 57 | $70 | $468 |
| Biopsy of prostate gland | 53 | $183 | $920 |
| Injection, garamycin, gentamicin, up to 80 mg | 49 | $2 | $14 |
| Urinalysis, manual | 48 | $3 | $18 |
| Removal of lymph nodes of both sides of pelvis using an endoscope | 46 | $258 | $3,223 |
| Surgical removal of prostate and surrounding lymph nodes using an endoscope | 46 | $924 | $7,119 |
| Office visit, established patient, complex (40-54 min) | 42 | $135 | $464 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 41 | $556 | $3,303 |
| Simple change of bladder tube | 34 | $69 | $448 |
| Simple surgical subtotal removal of prostate using laparoscope | 34 | $811 | $2,355 |
| New patient office visit (30-44 min) | 31 | $83 | $347 |
| New patient office visit, complex (60-74 min) | 29 | $159 | $664 |
| Diagnostic exam of bladder and urethra using an endoscope | 25 | $176 | $837 |
| Telephone medical discussion with physician, 21-30 minutes | 25 | $100 | $212 |
| Simple insertion of temporary bladder tube | 21 | $49 | $309 |
| Simple bladder irrigation and/or instillation | 18 | $57 | $346 |
| Telephone medical discussion with physician, 11-20 minutes | 13 | $60 | $138 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
The majority of payments (56%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in urology physician and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 2% for urology physician in TX.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Roehrborn is a clinical cardiology specialist, with above-average Medicare volume (top 22% in TX), and high industry engagement (speaking/promotional, top 2%), with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Roehrborn experienced with bcg treatment for bladder cancer?
Does Dr. Roehrborn receive payments from pharmaceutical companies?
How do Dr. Roehrborn's costs compare to other urology physicians in Dallas?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology